2016年 美骨质疏松症患者双膦酸盐长期应用指南.pdfVIP

REVIEW JJBMR Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research Robert A Adler,1 Ghada El-Hajj Fuleihan,2 Douglas C Bauer,3 Pauline M Camacho,4 Bart L Clarke,5 Gregory A Clines,6 Juliet E Compston,7 Matthew T Drake,5 Beatrice J Edwards,8 Murray J Favus,9 Susan L Greenspan,10 Ross McKinney Jr,11 Robert J Pignolo,12 and Deborah E Sellmeyer13 1McGuire Veterans Affairs Medical Center and Virginia Commonwealth University School of Medicine, Richmond, VA, USA 2American University of Beirut Medical Center, Beirut, Lebanon 3University of California, San Francisco, San Francisco, CA, USA 4 Loyola University of Chicago, Maywood, IL, USA 5Mayo Clinic College of Medicine, Rochester, MN, USA 6University of Michigan, Ann Arbor, MI, USA 7University of Cambridge School of Clinical Medicine, Cambridge, UK 8MD Anderson Cancer Center, Houston, TX, USA 9University of Chicago, Chicago, IL, USA 10University of Pittsburgh, Pittsburgh, PA, USA 11Duke University School of Medicine, Durham, NC, USA 12University of Pennsylvania, Philadelphia, PA, USA 13The Johns Hopkins Bayview Medical Center, Baltimore, MD, USA ABSTRACT Bisphosphonates (BPs) are the most commonly used medications for osteoporosis. This ASBMR report provides guidance on BP therapy duration with a risk-benefit perspective. Two trials provided evidence for long-term BP use. In the Fracture Intervention Trial Long-term Extension (FLEX), postmenopausal women receiving alendronate for 10 years had fewer clinical vertebral fractures than those switched to placebo after 5 years. In the HORIZON extension, women who received 6 annual infusions of zoledronic acid had fewer morphometric vertebral fracture